The Future of Clinical Trials and Pharmacovigilance

This year, Proventa debuted its successful online event format for the first time, providing experts from across the sector with an online forum just as useful and educational as our physical events have always been. During the recent Clinical Trials/Pharmacovigilance...

1 month ago
Pharmacovigilance,Clinical Development,Clinical Operations,News

The Future of Clinical Trials and Pharmacovigilance

This year, Proventa debuted its successful online event format for the first time, providing experts from across the sector with an online forum just as useful and educational as our physical events have always been. During the recent Clinical Trials/Pharmacovigilance...

1 month ago

Antibiotic Resistance: Is Pharma Doing Enough?

Developed resistances to certain antibiotics have occurred since their creation in the 1940s. Scientists found the first case of resistance just four years after antibiotics entered mass production. Only recently, however, has the issue taken a critical turn. Resistant strains of...

8 months ago
R&D,Pharmacovigilance,Biology

Antibiotic Resistance: Is Pharma Doing Enough?

Developed resistances to certain antibiotics have occurred since their creation in the 1940s. Scientists found the first case of resistance just four years after antibiotics entered mass production. Only recently, however, has the issue taken a critical turn. Resistant strains of...

8 months ago

AI and Pharmacovigilance ADR processing

Many of the problems that have long been inherent in Pharmacovigilance (PV) - such as historic limitations in the information that is published in case reports, analysis of electronic health records and integration - have found an answer in the...

12 months ago
R&D,Pharmacovigilance,Bioinformatics

AI and Pharmacovigilance ADR processing

Many of the problems that have long been inherent in Pharmacovigilance (PV) - such as historic limitations in the information that is published in case reports, analysis of electronic health records and integration - have found an answer in the...

12 months ago

The Abbvie-Allergan Deal: A Matter of Distrust?

Compared to the merger announcement itself, the industry reaction to the $63 billion Abbvie buyout of Allergan, announced this June, was no big surprise. Abbvie, seeking to replace its now-ageing blockbuster drug Humira, was the only suitor for the Botox...

1 year ago
Pharmacovigilance,News

The Abbvie-Allergan Deal: A Matter of Distrust?

Compared to the merger announcement itself, the industry reaction to the $63 billion Abbvie buyout of Allergan, announced this June, was no big surprise. Abbvie, seeking to replace its now-ageing blockbuster drug Humira, was the only suitor for the Botox...

1 year ago